The IP schedule in a data room lists what was filed. It does not show whether the claims are defensible, whether ownership is clean, or whether the portfolio actually covers the product being bought. In AI, cryptography, security and data investments, that gap frequently affects price, structure and timing.
We are retained by venture capital firms, growth equity investors, and strategic acquirers to evaluate the questions the schedule leaves open:
- Claim strength. Whether the claims are defensible against relevant prior art, including work absent from the seller’s disclosures or the examination record.
- Ownership. Whether the assignment chain and underlying obligations support the rights the company represents that it owns.
- Product coverage. Whether the claims reach the technology underlying the investment thesis, rather than peripheral features or an earlier product direction.
- Continuity. Whether trade secrets and data assets retain their protection and permitted uses after closing, including any restrictions triggered by the transaction.
Scoping
Engagements are scoped to the stage of the transaction.
Seed and pre-seed
At seed and pre-seed the question is binary: are there fundamental defects that would make a later exit impossible?
Scope
The initial review focuses on the foundations of the company’s IP position:
- Founder ownership. We examine whether relevant inventions and other contributions have been assigned to the company, including work that preceded incorporation.
- Prior obligations. We review employment and other commitments that may give a former employer or institution rights in the technology.
- Patent defensibility. We assess the basic relationship between the claimed invention, known prior art, and the product the company intends to develop.
- Material red flags. We identify apparent defects or restrictions that warrant further investigation before financing or could complicate a later exit.
Deliverables
The deliverable is a short executive memo with material issues and recommended next steps.
Series A
At Series A the diligence informs valuation and structure.
Scope
We inventory patents, pending applications, trade secrets, proprietary data, and inbound and outbound licenses.
- Ownership. We trace the assignment chain and reconcile the asset inventory with the agreements and records supporting the company’s rights.
- Patent strength. We evaluate claim strength and prior-art exposure, including art the examiner did not reach, in relation to the technology supporting the valuation.
- Data. We review training-data provenance and the permissions governing acquisition, model development, and intended commercial use.
- Confidentiality. We assess whether trade-secret practices protect the know-how on which the business depends, including access controls and confidentiality obligations.
Deliverables
Deliverables include a detailed report, executive summary, risk matrix, and remediation roadmap.
Series B and later, growth equity, and acquisitions
Scope
For Series B and later, growth equity, and acquisitions we add:
- Freedom to operate. We examine relevant third-party claims against the product architecture and assess the available responses to identified exposure.
- Litigation risk. We evaluate disputes, asserted claims, and other evidence of potential enforcement exposure in the context of the proposed transaction.
- License continuity. We review change-of-control, assignment, termination, and other material provisions that may affect access to essential technology after closing.
- Management interviews. We test the documentary record against the development history, operating practices, and dependencies described by the people responsible for the technology.
- Competitive positioning. We assess how the portfolio supports differentiation and planned growth, including gaps between the company’s commercial narrative and its technical protection.
Deliverables
The report is suitable for investment-committee presentation, with follow-up through closing.
What we examine
Patent portfolio quality
- Coverage of the product. We map claim limitations to the product’s operation, distinguishing protection of commercially important features from coverage that is incidental to the business.
- Defensibility of the claims. We examine relevant prior art, including art the examiner missed, and the prosecution record that informs the scope and strength of the claims.
- Support for future plans. We consider whether the portfolio extends to planned development and market entry, or whether the investment thesis depends on protection that has yet to be secured.
For AI inventions this includes Section 101 eligibility risk. For cryptography it includes the distinct 101 and 112 posture of implementations of mathematical constructions.
IP ownership chain
A portfolio is only as valuable as its owner can enforce. We trace ownership from original invention through every assignment, employment agreement, and corporate transaction.
Missing executions, assignments to defunct entities, and inventions made before assignment obligations attached can render patents unenforceable, unlicensable, or uninsurable. Companies that grew through acquisition or reorganization frequently surface surprises that change deal structure.
Training data and proprietary data
For AI companies the most valuable asset is often the data, and the hardest question is whether the company has the rights it needs.
We review:
- Acquisition practices. We trace how datasets were collected or obtained and whether the records establish their sources, provenance, and applicable permissions.
- Licensing documentation. We examine permitted uses, restrictions, and transfer provisions against the company’s actual workflows and proposed commercial activities.
- Terms-of-service compliance. We assess whether the methods of accessing and using source material are consistent with the terms governing that access.
- Claims exposure. We evaluate potential copyright, privacy, and contractual claims, identifying the uses or documentation gaps that could affect transaction terms or require remediation.
Where documentation is thin we quantify the risk in terms an investment committee can act on.
Trade secret protection
Trade secrets protect what patents cannot: model architectures, training methodologies, unpublished algorithms, and security processes.
We assess:
- Identification. We examine whether the company can identify the confidential information it relies on, distinguish it from public knowledge, and locate the supporting records.
- Protection practices. We assess confidentiality agreements, access restrictions, and handling practices against the way the information is actually used and shared.
- Continuity of protection. We consider how a change in ownership or a departing employee affects access, confidentiality obligations, and the company’s ability to retain the relevant know-how.
Why this work is different in our domains
The risks that matter, the documents that contain them, and the judgment required to separate signal from noise differ across the fields where we work.
Artificial intelligence
In artificial intelligence, training-data rights and provenance are a frequent source of undisclosed risk. Model-weight and derivative-model licensing raise questions most diligence checklists do not contain. Section 101 eligibility is a persistent issue for machine-learning inventions.
Post-quantum cryptography
In post-quantum cryptography, patent positioning around standardization affects both valuation and freedom to commercialize. Claims on mathematical constructions and claims on their implementations carry different risks. Export controls and the publication histories of the inventors matter more than the public record suggests.
Cybersecurity
In cybersecurity the tension between trade-secret protection and patent disclosure is substantive. The most valuable asset may be the one never described in a patent or public filing; the diligence question is whether that asset is protected, documented, and transferable without losing its value.
Data-driven systems
In data-driven systems the relevant vocabulary is field restrictions, derivative-data rights, aggregation rights, cross-border transfer obligations, and the allocation of liability for data-quality and data-lineage claims.
Biomedical research and decentralized science
In biomedical research and decentralized science, diligence can examine the scientific and development records supporting a platform’s claims, institutional rights in research outputs, and permissions governing biomedical datasets and software. For blockchain-based projects, the review can also assess how token-linked rights and governance correspond to the underlying ownership, licenses, and research agreements.